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A ligand-specific blockade of the integrin Mac-1
selectively targets pathologic inflammation while
maintaining protective host-defense
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Integrin-based therapeutics have garnered considerable interest in the medical treatment of
inflammation. Integrins mediate the fast recruitment of monocytes and neutrophils to the site
of inflammation, but are also required for host defense, limiting their therapeutic use. Here,
we report a novel monoclonal antibody, anti-M7, that specifically blocks the interaction of the
integrin Mac-1 with its pro-inflammatory ligand CD40L, while not interfering with alternative
ligands. Anti-M7 selectively reduces leukocyte recruitment in vitro and in vivo. In contrast,
conventional anti-Mac-1 therapy is not specific and blocks a broad repertoire of integrin
functionality, inhibits phagocytosis, promotes apoptosis, and fuels a cytokine storm in vivo.
Whereas conventional anti-integrin therapy potentiates bacterial sepsis, bacteremia,
and mortality, a ligand-specific intervention with anti-M7 is protective. These findings deepen
our understanding of ligand-specific integrin functions and open a path for a new field of
ligand-targeted anti-integrin therapy to prevent inflammatory conditions.
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Inflammation drives many diseases, including athero-sclerosis1,2, type 2 diabetes3, neurodegeneration4, and sepsis5.Targeting the inflammatory response might ameliorate these
conditions6. Yet, the critical role of the inflammatory response in
many biological processes such as regeneration, thrombosis, and
host defense presents a major limitation to such strategies7. For
example, glucocorticoids potently inhibit inflammation, but have
multiple undesired actions8. COX-2 inhibitors can suppress
inflammation, but nonetheless worsen cardiovascular outcomes9.
Inflammation involves the recruitment of leukocytes to the site
of injury, typically facilitated by integrins such as Mac-1 (αMβ2,
CD11b/CD18)10. The adhesion molecule Mac-1 can undergo
rapid activation yielding a conformational change that increases
affinity for its ligands that enable it to mediate rolling, firm
adhesion, and transmigration of leukocytes into inflamed tis-
sue11–13. Therapeutic or genetic inhibition of Mac-1 highly
effectively limits experimental atherosclerosis14, neo-intima for-
mation15,16, adipose tissue inflammation17, ischemic kidney
injury18, and glomerulonephritis19,20. Beyond its role in inflam-
mation, Mac-1 was initially named CR3 (complement receptor 3)
due to its ability to bind complement factors, such as iC3b21,
reflecting its broad role in host defense22–24, wound healing25,
thrombosis26,27, and various other myeloid cell effector func-
tions28–30. Myeloid cells, including monocytes, macrophages, and
neutrophils express Mac-1, as do NK cells, and to a smaller extent
activated lymphocytes31. Mac-1’s functional diversity is reflected
by ligand binding to a large repertoire of proteins and pro-
teoglycans, including ICAM-132, fibrinogen33, fibronectin34,
vitronectin34, heparin35, GPIbα26, RAGE36, endothelial protein
C-receptor (EPCR)37, CD40L14, and others38. Inhibition of
Mac-1 could thus serve as a promising therapeutic strategy in
inflammatory disease39,40. Its major role in host defense, regen-
eration, and thrombosis, however, could limit its therapeutic
applicability.
To overcome these limitations, we hypothesized that the
inactivation of distinct integrin functions involved in inflamma-
tory, but not in regenerative or immune pathways, could result
from selective blockade of Mac-1’s interaction to specific ligands,
while not affecting others. For proof-of-concept studies we
designed a monoclonal antibody, that targets specifically the
EQLKKSKTL motif in Mac-1, required to bind to its multipotent
ligand CD40L14,41,42. We successfully generated this antibody
and compared its effect to conventional anti-Mac-1 blockade
experimentally in in vivo leukocyte recruitment, peritoneal
inflammation, sterile and polymicrobial sepsis. In conclusion, we
report that a ligand-specific anti-Mac-1 therapy is superior to
unspecific, conventional blocking strategies —in particular in
conditions that are driven by inflammation and impaired host
defense simultaneously, such as polymicrobial sepsis.
Results
The antibody anti-M7 targets the Mac-1/CD40L-binding site.
We previously demonstrated that CD40L selectively binds to the
EQLKKSKTL motif (M7) within the Mac-1 ligand-binding
I-domain41. To generate a specific inhibitor of the human binding
site that can bind and block the M7 motif within the Mac-1 I-
domain, we immunized mice with the human peptide V160-S172
coupled to diphtheria toxoid. The M7 sequence is highly con-
served between the human and murine protein sequence (Fig. 1a).
Among several hybridoma clones that demonstrated high-affinity
binding to the immobilized peptide M7 in a solid-phase binding
assay, one clone, termed anti-M7 (mouse IgG2bκ), showed a
specific inhibition of Mac-1-CD40L binding, but not of the
binding to other ligands. Anti-M7 bound to a CHO cell line that
overexpresses non-activated human Mac-1 (Mac-1 WT) and
permanently activated human Mac-1 (Mac-1 del)43, but did not
bind to control CHO cells (CHO) in western blot (Fig. 1b,
Supplementary Figure 1), demonstrating that the antibody binds
to its intended target protein. Anti-M7 bound in a concentration-
dependent manner to the immobilized peptides M7
(EQLKKSKTL), but not to the control peptides scrambled sM7
(KLSLEKQTK) or the peptide M8 (EEFRIHFT), which locates
near the peptide sequence M7 (Fig. 1c). To quantify the binding
of anti-M7 to Mac-1 expressing human cells, we coupled the
antibody to the fluorochrome Alexa-647 and validated that anti-
M7 bound concentration-dependently to human leukocytes that
express Mac-1, such as monocytes and neutrophils (Fig. 1d).
These findings demonstrate that anti-M7 specifically binds to the
peptide sequence M7 within the intact human Mac-1 I-domain.
To test whether anti-M7 blocks the functional interaction of
human Mac-1 with human CD40L, we tested the adhesion of
CHO-Mac-1 del cells to immobilized CD40L in a static adhesion
assay. Anti-M7 blocked cell adhesion by 65.6± 7.2% (mean±
SEM), an effect nearly as strong as the anti-human Mac-1
reference clone 2LPM19c, a pan I-domain blocking antibody
(inhibition by 92.7± 2.0%, Fig. 1e, f). Notably, the adhesion of
CHO cells expressing the non-permanently activated human
Mac-1 (WT Mac-1) was neutralized by two conventional anti-
human Mac-1 clones (2LPM19c and IRF44), but not by anti-M7,
indicating that anti-M7 preferentially blocked the integrin’s high-
affinity interaction with CD40L. CHO cells not expressing Mac-1
did not adhere to CD40L (Supplementary Figure 2). Different
ligands can bind to separate or overlapping binding regions
within the Mac-1 I-domain. To test whether anti-M7 is func-
tionally specific for CD40L binding, a panel of established Mac-1
ligands, including fibrinogen, vitronectin, JAM-C, ICAM-1, NIF,
heparin, and RAGE, were separately immobilized and binding of
Mac-1-del cells was tested in the presence of anti-M7 and anti-
Mac-1 (2LPM19c), respectively. Anti-Mac-1 blocked each of the
interactions highly efficient, while anti-M7 blocked cell adhesion
to CD40L only (Fig. 1f). Another control experiment verified that
Fab fragments of anti-M7 sufficed for its specific blocking activity
without depending on unspecific Fc-receptor interactions
(Fig. 1g). These data demonstrate that anti-M7 specifically inhi-
bits the CD40L/Mac-1 interaction.
Anti-M7 prevents inflammatory leukocyte recruitment. Mac-1
is a prerequisite for leukocyte recruitment in inflammation11–13.
It serves as receptor for different ligands expressed on the
inflamed endothelium, including ICAM-1, RAGE, and CD40L
and mediates slow rolling, firm adhesion, and subsequent trans-
migration of myeloid cells11,36,41. We have recently shown that a
peptide-based inhibition of the CD40L binding epitope that
interacts with Mac-1 protects from leukocyte accumulation by
efficiently blocking cellular adhesion41. Here, we interrogated
whether blocking the M7-binding sequence directly would be
equally efficient in vitro and in vivo. First, we verified that the
mouse anti-human M7 antibody blocks the static adhesion of
Mac-1 expressing mouse peritoneal macrophages and mouse
CD40L (Fig. 2a). An anti-mouse Mac-1 antibody (clone M1/70)
served as control. Next, we tested whether anti-M7 blocks the
cellular adhesion under physiological flow conditions. Therefore,
murine monocytic RAW-cells were allowed to adhere on TNFα-
primed primary, murine endothelial cells in vitro in a flow
chamber assay. The number of adhering cells decreased after
incubation with anti-M7, indicating a requirement for CD40L/
Mac-1 interaction for leukocyte arrest on inflamed endothelial
cells (Fig. 2b). To test the antibody’s in vivo applicability,
we prepared Fab fragments of anti-M7, anti-Mac-1 (M1/70), a
control-IgG, and antibodies directed against ICAM-1, LFA-1
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(CD11/CD18), and RAGE to avoid unspecific Fc-receptor
interactions. Anti-M7 did not change peripheral leukocyte counts
after an i.p. injection (Supplementary Figure 3). In intravital
microscopy (Fig. 2c) of inflamed mesenteric venules, the number
of adhering (Fig. 2d) but not of rolling leukocytes (Fig. 2e) fell
after anti-M7 injection. In accordance, leukocyte rolling velocity,
displayed as cumulative frequency, did not change (Fig. 2f).
Notably, this effect was comparable to the effect after blockade of
the receptor/ligand pairs Mac-1/ICAM-1, LFA-1/ICAM-1, and
Mac-1/RAGE. Anti-M7 failed to reduce leukocyte recruitment in
Mac-1−/− mice (Fig. 2g), suggesting specificity of the antibody. In
addition, we excluded that anti-M7 induces leukocyte depletion
after injection (data not shown). To test whether impaired
monocyte arrest would affect down-stream effects of the integrin,
such as leukocyte transmigration, mice expressing GFP in
monocytes (CX3CR1-GFP) were subjected to intravital micro-
scopy in the presence of IgG or anti-M7 Fab preparations after a
TNFα challenge for 4 h (Fig. 2h). Fewer monocytes migrated to
the para-vascular space after anti-M7 treatment (Fig. 2i). Leu-
kocyte recruitment during sepsis and abdominal inflammation
caused by an i.p. TNFα injection occurs through high endothelial
venules (HEVs) in the greater omentum44. Therefore, we applied
confocal intravital microscopy of this region after local TNFα
treatment of LysM-GFP reporter mice that express GFP in
myeloid cells. Anti-M7 treatment blocked the emigration of
LysM+ myeloid cells to the para-vascular space (Fig. 2j, left and
middle panel) and induced a predominant crawling behavior of
LysM-GFP+ neutrophils in the vascular lumen (right panel),
indicating a defect in Mac-1-mediated firm adhesion. Time lapse
tracking of single cells demonstrated that myeloid cells in mice
injected with anti-M7 were less likely to transmigrate from
inflamed venules. In addition to lowered cell adhesion, we
observed that plasma levels of the pro-inflammatory cytokines
TNFα, IL-6, and MCP-1 fell significantly in mice after an anti-M7
treatment (Fig. 2k). Finally, anti-M7 efficiently reduced the
number of macrophages in the peritoneal cavity 72 h after
induction of a sterile, thioglycollate-induced peritonitis (Fig. 2l).
In addition, anti-M7 improved, while an anti-Mac-1 treatment
enhanced, the levels of pro-inflammatory cytokines in the peri-
toneal cavity (Supplementary Figure 4). These results indicate
that leukocyte adhesion, transmigration, and accumulation pro-
ceeds in vitro and in vivo via binding of CD40L with Mac-1 —an
interaction that anti-M7 effectively blocked.
Anti-M7 does not induce integrin outside-in signaling. Besides
mediating a leukocyte-endothelial cell or leukocyte-leukocyte
cross-talk, Mac-1 engagement by soluble or membrane-bound
ligands can initiate down-stream pro-inflammatory signaling
events13,17,42. Such outside-in-signaling45, which comprises
activation of the MAP-kinases ERK and p38 is also observed
after anti-Mac-1 antibody binding7,46. We previously showed
that CD40L is a biased agonist that does not induce outside-in
signaling events38,41. Our observation that a treatment with anti-
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Fig. 2 Treatment with anti-M7 prevents inflammatory leukocyte recruitment in vitro and in vivo. a Murine peritoneal macrophages were incubated on
dishes coated with mouse CD40L in the presence of 10μg/ml of IgG, anti-M7, or anti-Mac-1 (clone M1/70). Adhering cells were normalized to % of the
IgG-treatment. b Murine RAW-cell adhesion on TNFα-primed murine endothelial cells under physiological flow in the presence of IgG or anti-M7
antibodies (10 μg/ml). c–f C57Bl/6 mice were injected i.p. with 200 ng TNFα and 15min before microscopy with Fab fragments of an IgG control antibody,
or antibodies against RAGE, ICAM-1, LFA-1, Mac-1 (clone M1/70), or anti-M7 (100 μg i.p.). Leukocyte recruitment was monitored by intravital microscopy
4 h later: Adhering (d) and rolling leukocytes (e) were quantified as % of IgG. (f) Cumulative frequency of leukocyte rolling velocity. g Leukocyte adhesion
in intravital microscopy in IgG or anti-M7 treated WT and Mac-1−/− mice. h, i Number of CX3CR1-GFP+ monocytes (white arrows) in the para-vascular
space 4 h after treatment with IgG or anti-M7 and 200ng TNFα. j Confocal in vivo imaging of the greater omentum after local stimulation with TNFα and
i.v. injection of the indicated antibodies (100 μg) in LysM-GFP reporter mice. LysM-GFP+ myeloid cells were tracked over time. Time lapse and cell tracking
is shown over 15 min (right panel). k Plasma cytokine levels of mice subjected to intravital microscopy after IgG or anti-M7 Fab treatment. l Peritoneal
exudate cells (PECs) 72 h after induction of a sterile peritonitis and the indicated antibody treatment. Scale bars represent 100μm (c, h, j). Error bars
indicate mean± SEM. Statistical significance was assessed by a two-sided, unpaired Student’s T-test between the indicated groups (a, b, g, i, k, l) or in
comparison to IgG-treatment (d, e). *P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001. N≥ 3 independent experiments (a, b). N≥ 10 mice per group (d, e,
f, g), N≥ 6 mice per group (l, h)
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Mac-1 protected from recruitment to the peritoneal cavity
(Fig. 2l) while enhancing pro-inflammatory cytokine expression
(Supplementary Figure 4), tempted us to verify potential outside-
in signaling events promoted by anti-M7 and anti-Mac-1.
Therefore, we collected thioglycollate-elicited peritoneal macro-
phages from male, 8-week-old C57Bl/6 mice and incubated these
with 10 μg/ml of either mouse IgG, anti-human Mac-1 (clone
2LPM19c) as species-mismatch control, anti-mouse Mac-1 (clone
M1/70), or anti-M7 for 30 min. Anti-Mac-1 treatment (M1/70)
induced phosphorylation of ERK and p38 as quantified by an
elevated ratio of the phosphorylated proteins in western blotting
(Fig. 3a, b, Supplementary Figure 5, 6). Species-mismatched anti-
Mac-1 (2LPM19c) or anti-M7 showed no activation of these
MAP-kinases, indicating that the binding epitope M7 targeted by
anti-M7 is not involved in outside-in signaling. To assess the
in vivo relevance of such anti-Mac-1 agonism, mice received anti-
Mac-1 antibodies from various clones i.p. and serum
concentration of IL-6, TNFα, and MCP-1 were quantified 4 h
after injection. The anti-Mac-1 reference clone in the mouse, M1/
70, strongly elevated cytokine levels, while anti-M7 did not
(Fig. 3c). Pro-inflammatory cytokine concentrations also
increased in cultured mouse macrophages after antibody co-
incubation (data not shown). Vice versa, human monocyte-
derived macrophages showed the same pattern in anti-M7 and
anti-human Mac-1 (reference clone 2LPM19c) stimulated mac-
rophages (Fig. 3d). To further verify that anti-M7 does not act as
an agonist for Mac-1, we quantified binding of the two anti-
human β2-subunit antibodies KIM127 and Mab24, which are
indicating cellular activation and subsequent changes in integrin
conformation by detecting β2-extension (KIM127) and β2 high-
affinity conformation (Mab24)47, in human primary neutrophils
in a real-time flow cytometry binding assay (Fig. 3e–i). Only
binding of Mab24 was slightly reduced after co-incubation with
the human chemokine IL-8, which is required for full integrin
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activation, and anti-M7, while we observed no changes in the
baseline activation. These findings suggest that anti-M7 targets an
epitope on Mac-1 that does not cause outside-in signaling and
pro-inflammatory cytokine secretion in Mac-1 expressing cells
during anti-integrin therapy.
A ligand-specific blockade of Mac-1 improves sepsis. Aberrant
activation of leukocytes and excessive cytokine secretion
increase disease severity and mortality in sepsis48–50. On the
other hand, integrins are required for host defense, demonstrated
by the requirement for Mac-1 to clear bacteria22–24,51. Clinically,
blood concentrations of soluble CD40L52 and sCD1853 are
associated with sepsis, suggesting that both, Mac-1 and CD40L,
participate in the acute inflammatory response in sepsis. To
outweigh its conflicting effects on host defense and pathologic
inflammation, we hypothesized that a ligand-specific blockade
would be superior to an unspecific inhibition of Mac-1 in poly-
microbial sepsis. We first evaluated the effects of anti-M7 in a
sterile systemic inflammatory response syndrome (SIRS) induced
by an i.p. injection of LPS, a known TLR agonist. We applied a
novel FACS gating strategy that made it possible to identify
several Mac-1+ cell subsets, including granulocytes, F4/80low
(monocyte-derived) and F4/80high (resident) macrophages, den-
dritic cells, myeloid-derived suppressor cells (MDSCs), and others
(Fig. 4a, b, Supplementary Figure 7). 20 h after injection of a
medium dose of LPS (20μg) we observed an increase in total cell
numbers in the peritoneal cavity (not shown) with a relative
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Fig. 4 Ligand-specific Mac-1 inhibition improves sterile and bacterial sepsis by preventing excessive inflammation and enhanced bacterial clearance. A
systemic inflammatory response syndrome (SIRS) induced in C57Bl/6 mice by an i.p. injection of 20μg LPS (0111:B4). a Leukocyte accumulation in the
peritoneal cavity was characterized with a 15-parameter panel in flow cytometry. bMacrophages were sub-divided into F4/80low and F4/80high. c Relative
myeloid cell composition in the peritoneal cavity was compared in untreated mice (left cake diagram), after LPS injection (LPS), and after surgical induction
of a cecal ligation and puncture (CLP) polymicrobial sepsis. d Male, 8-week-old C57Bl/6 mice were injected with 20 μg LPS (0111:B4) and 50 μg of the
indicated antibody clones. After 20 h, myeloid cell populations were quantified in the peritoneal cavity (expressed as % of IgG-treated animals). e Myeloid
cell populations in the peritoneal cavity 20 h after surgical induction of a CLP sepsis in male, 8-week-old C57Bl/6 mice. 1 h before surgery 50μg of the
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of CLP sepsis. Relative survival was calculated and displayed as Kaplan–Maier survival curve. Error bars indicate mean± SEM. Statistical significance was
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increase of granulocytes (Fig. 4c). Anti-M7 efficiently blocked the
infiltration of Mac-1+ myeloid cells, in particular of granulocytes
and F4/80low macrophages (Fig. 4d), validating its neutralizing
effect on inflammatory cell recruitment. This effect was not
caused by changes in the frequency of apoptosis in particular
myeloid cell subsets, while an unspecific anti-Mac-1 inhibition
increased the percentage of apoptotic macrophages (Supple-
mentary Figure 8). Also, we did not detect changes in the gen-
eration of reactive oxygen species as a surrogate for myeloid cell
effector function (Supplementary Figure 9) in anti-M7 treated
mice.
We next performed a model of polymicrobial sepsis by a
surgical cecal ligation and puncture (CLP) that causes an increase
in granulocytes and macrophages in the peritoneal cavity (Fig. 4c).
A preventative injection of anti-M7 dampened this increase in
myeloid cell recruitment to the peritoneal cavity in 8-week-old,
male C57Bl/6 mice, while an unspecific anti-Mac-1 treatment was
only partially effective (Fig. 4e). The effect of anti-M7 was
consistent in female mice and aged mice (40 weeks, Supplemen-
tary Figure 10). Anti-M7 failed when injected 2 h after the onset
of sepsis (Supplementary Figure 11), confirming the necessity for
an early intervention to reduce immediate myeloid cell infiltra-
tion44. Systemically, anti-M7 treatment attenuated the CLP-
induced increase in inflammatory monocytosis and of the acute-
phase protein SAA (Supplementary Figure 12), indicating that
anti-M7 specifically reduced the excessive inflammatory response
during sepsis. Accordingly, we did not find an inhibitory effect of
anti-M7 on peritoneal leukocyte recruitment in a less severe CLP
sepsis model, where peritoneal cell numbers did not relevantly
increase over baseline (Supplementary Figure 13). Surprisingly,
anti-M7 improved bacterial clearance in the plasma, while anti-
Mac-1 worsened bacterial load in both, plasma and in the
peritoneal cavity (Fig. 4f). This tempted us to directly test
bacterial uptake, which was increased in anti-M7 treated mice,
likely by favoring complement iC3b binding (Fig. 4g, Supple-
mentary Figure 14).
Bacterial uptake and antigen-presentation is crucial to induce
an antigen-specific immune response. In accordance, we detected
higher numbers of activated T cells with an effector and memory
phenotype, decreased systemic levels of the immune-suppressive
cytokine IL-10 (Supplementary Figure 12, 15), a reduced number
of immune-dampening MDSCs in the peritoneal cavity (within
the Ly6-C− population, Fig. 4d), and increased IgM antibody
levels (Supplementary Figure 12), indicating an improvement in
host defense. In contrast, histology of organs vulnerable for septic
injury, such as the kidney, was not affected by an anti-M7
treatment 20 h after CLP, although we detected an expected
decrease in granulocyte accumulation (Supplementary Figure 16,
17). Finally, we assessed whether our ligand-specific approach
ultimately affects survival during sepsis. After CLP, mice received
Fab preparations of IgG, anti-Mac-1, or anti-M7 at 1 h before, 48,
and 96 h after surgery. Survival rates were calculated by
Kaplan–Maier analysis and compared by log-rank testing. Anti-
M7 treated showed a lethality of 60% at the end of the study
compared with 93% in IgG-treated mice (log-rank test, P = 0.027,
Fig. 4j). All animals treated with anti-Mac-1 died. These findings
indicate that —in contrast to an unspecific blockade— a ligand-
specific anti-integrin therapy can reduce excessive inflammation
without negatively affecting host defense.
Discussion
The adhesion receptor Mac-1 mediates a variety of inflammatory
mechanisms10. Although Mac-1 has attraction as a target for
limiting leukocyte recruitment in atherosclerosis and other acute
and chronic inflammatory conditions14,41, various undesired
actions of blocking this integrin temper enthusiasm for this
approach25,54. For example, patients with leukocyte adhesion
deficiency (LAD), caused by defects of the integrins Mac-1,
LFA-1, and CD11c in their common β2-subunit, causes immune
deficiency55. Therefore, global therapeutic inhibition of
Mac-1 may have unfavorable consequences. To circumvent this
limitation, we designed a novel monoclonal antibody that
targets specifically the binding of CD40L to Mac-1’s major
ligand-binding I-domain within the αM-subunit of the integrin.
We have previously shown that CD40L is a biased Mac-1 ligand,
stimulating leukocyte recruitment by mediating binding to
endothelial cell-expressed CD40L, without activating outside-in
signaling38,41. In this previous study, peptide-based inhibition
of the CD40L/Mac-1 interaction did not interfere with
CD40L/CD40, Mac-1/GP1bα, or Mac-1/ICAM-1 binding, sug-
gesting unique binding epitopes on each of the molecules41.
Therefore, specifically targeting the CD40L-Mac-1 interaction
could obviate some of the unwanted effects of global Mac-1
blockade.
The β2-integrins Mac-1 (CD11b/CD18), LFA-1 (CD11a/
CD18), along with members of the β1- and β3-integrin families
support leukocyte recruitment to inflamed tissue11–13,56.
Although several studies have demonstrated that reducing mye-
loid cell accumulation by inhibition of the integrins α3β1 and
αVβ3 decreases aberrant leukocyte infiltration in sepsis and
protects from sepsis-related mortality48–50, neutralization of Mac-
1 results in a strong inhibition of leukocyte mobilization, but also
causes an accelerated bacterial sepsis with a higher mortality22–
24,52. This phenomenon is best explained by the observation that
unlike α3β1 and αVβ3, Mac-1 is necessary to bind the comple-
ment factor iC3b, to opsonize bacteria, and to ultimately clear
bacterial particles22–24,52,54. Unexpectedly, we found that binding
of anti-M7 to its epitope M7 within the Mac-1 I-domain,
increased iC3b binding, promoted phagocytosis, and improved
adaptive T cell immunity. Currently, it remains unclear how an
engagement of the epitope M7 enhances iC3b binding: The
binding epitopes for iC3b within the I-domain have been located
to the residues P147-R152, P201-K217, and K245-R261 within the αM
I-domain57–59 and are therefore distinct from the epitope tar-
geted by anti-M7 (E162-L170). P147-R152 (according peptide M1),
however, is a flanking sequence of M7 (Fig. 1a). In a previous
study, the contribution of M1 to CD40L binding could not be
clearly excluded41. It therefore remains speculative whether
CD40L has a partial, low-affinity interaction with M1 that is lost
after inhibition of M7, and thus would make this epitope re-
accessible to bind iC3b. As proposed previously, the M7 epitope
may also (sterically) regulate iC3b binding due to a regulatory
activity of this domain60.
That anti-M7 specifically blocked the high-affinity interaction
of Mac-1 with CD40L and therefore was selective to high-grade
(pathologic), but not low-grade (beneficial), inflammation, might
represent an additional mechanism by which a CD40L-specific
blockade of Mac-1 could limit sepsis-related mortality. Here, we
show by several in vitro and in vivo approaches that in addition
to the established ligands ICAM-161 and RAGE36, CD40L
represents a powerful adhesive ligand that is expressed on
inflamed endothelial cells41,42. Anti-M7 specifically blocked the
interaction of Mac-1 with CD40L, but not with ICAM-1 or
RAGE. Overall, anti-M7 was less effective compared to anti-Mac-
1 or anti-ICAM-1 treatment. In contrast to an unspecific anti-
Mac-1 treatment, which blocked adhesion and rolling of leuko-
cytes, anti-M7 only blocked cellular adhesion. These findings are
in accord with previous observations11,32,41 and point out that the
interaction of Mac-1 with one or more of its alternative ligands,
but not with CD40L, may mediate leukocyte rolling in TNF-α
stimulated mesenteric venules. Notably, neither anti-Mac-1, nor
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-02896-8 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:525 |DOI: 10.1038/s41467-018-02896-8 |www.nature.com/naturecommunications 7
anti-M7 caused a depletion of leukocytes, ruling out a reduction
of the circulating leukocyte pool as potential explanation for this
effect. In addition, anti-M7 lost its ability to block leukocyte
recruitment in the setting of a milder CLP procedure. These
results indicate that the Mac-1/CD40L interaction selectively
contributes to aberrant inflammation by blocking firm adhesion
and transmigration of leukocytes in the setting of acute
inflammation.
The role of pro-inflammatory cytokine secretion in sepsis
remains controversial. Depending on the specific context, dose,
and location, these can either improve or aggravate host
defense62. However, some therapeutic strategies to block aberrant
cytokines have been demonstrated efficacy in experimental sepsis:
blocking IL-10, an immuno-suppressive cytokine, improves sur-
vival during CLP63. Genetic inhibition of IL-3, a driver of mye-
lopoiesis, reduced mortality64. Likewise, mice deficient for the
receptor of TNF survived significantly longer than WT mice65. In
this study, we observed that the treatment with anti-M7
decreased, while treatment with a conventional anti-Mac-1 anti-
body clone (M1/70 in the mouse and 2LPM19c in humans)
strongly increased systemic and local pro-inflammatory cytokine
secretion. These findings confirm previous reports on isolated
macrophages and likely result from outside-in signaling by non-
selective antibody binding66, an action avoided by anti-M7. The
decrease in cytokines observed for anti-M7, in contrast, is likely
caused by a reduction of cell infiltration and subsequent cytokine
secretion by these cells36 without an induction of outside-in-
signaling. During sepsis, some cytokines released by myeloid cells
or lymphocytes can further fuel myeloid cell recruitment by
driving monocyte egress from the bone marrow or the spleen64,67
or by secreting chemokines, such as MCP-1. Selective Mac-1
blockade by anti-M7 may avoid this positive feedback loop by
inhibiting TNFα, MCP-1, or IL-10. In line, anti-M7 treatment
attenuated inflammatory monocytosis post CLP. The decrease of
IL-10 may also stem from a decrease of immune-suppressive
MDSCs.
The highly promiscuous integrin Mac-1 interacts with more
than 40 different ligands, for most of which we lack knowledge of
the detailed molecular mechanisms of binding13,38. Therefore,
other ligands may share the CD40L-binding site. However, the
data presented here suggest that CD40L does not share many
features with other Mac-1 ligands: (I) While binding epitopes
identified for fibrinogen and other ligands show overlapping
regions30,33, the EQLKKSKTL motif within the Mac-1 I-domain
has not been reported to be involved in binding of alternative
ligands41, (II) neither CD40L itself, nor anti-M7 induced integrin
outside-in signaling, while many other ligands do38,46, (III)
CD40L’s interaction with Mac-1 does not dampen immune
function, while most of Mac-1 ligands, such as fibrinogen, par-
ticipate in multiple pathological processes30. Our data shown here
and previously41 indicate that immune function, hemostasis, and
regenerative responses do not involve binding of CD40L to Mac-
1. The concept of such ligand/function-specificity was recently
supported by the finding that inhibition of the M2 sequence
required for binding of GP1bα selectively reduces the cross-talk of
leukocyte and platelets in thrombosis27.
Taken together, here, we present a novel and powerful strategy
to selectively target the CD40L-binding motif on Mac-1 with the
monoclonal antibody anti-M7. This antibody is selective for the
targeted binding site, does not interfere with alternative binding
partners, and —in contrast to conventional anti-Mac-1 anti-
bodies— does not affect host defense. We propose that a ligand-
targeted anti-integrin therapy may represent a promising therapy
against inflammation in cardiovascular disease. Future research
will have to clarify whether this concept is translatable to human
disease.
Methods
Animal protocols. Male mice on a C57BL/6 background received a standard chow
diet. All mice were maintained under standardized conditions (12 h light, 12 h dark
cycle) and had access to food and water ad libitum. At the age of 8 or 40 weeks,
mice were subjected to intravital microscopy, sterile peritonitis, LPS injection, or
CLP sepsis. As indicated, we additionally tested female mice when indicated in the
results section. Treatment with antibodies (Fab fragment preparations, 50 μg/
mouse) was performed by intraperitoneal or intravenous injection at a volume of
100μL per injection. In some intravital experiments, GFP-transgenic animals under
the control of CXCR3-promoter (CXCR3-GFP) or LysM (LysM-GFP), or Mac-1-
deficient mice (Mac-1−/−, B6.129S4-Itgamtm1Myd/J, Jackson Laboratories, stock
number: 003991) and aged-matched WT littermate controls were subjected to
intravital microscopy.
Study approval. All experimental animal protocols were approved by the
animal ethics committee of the Alfred Medical Research and Education Precinct
(AMREP), Melbourne, Australia, the local animal ethics committee at the
University of Freiburg, and at the La Jolla Institute for Allergy and Immunology,
CA, USA. All procedures were carried out in accordance with institutional
guidelines.
Antibody generation. An antibody specific for a peptide corresponding to
Mac-1 I-domain sequence V160-S172 was obtained by immunizing mice with the
peptide C-VMEQLKKSKTLFS-NH2 coupled to diphtheria toxoid (Monash
Antibody Technologies Facility, Monash University, Melbourne, Australia).
For further selection, hybridoma supernatants were screened for binding to the
peptide M7 in solid-phase binding assays41. Among different clones with high
affinity to M7, one clone (RC3), subsequently termed anti-M7, was further
characterized.
Antibody-binding studies. Specific binding of the antibody anti-M7 to the
immobilized peptides M7 (EQLKKSKTL), or the control peptides scrambled sM7
(KLSLEKQTK), or the peptide M8 (EEFRIHFT)41 was tested in a solid-phase
binding with immobilized peptides in 96-well ELISA plates (Nunc). Binding of
anti-M7 was detected by addition of biotinylated anti-mouse IgG and subsequent
color reaction after the incubation with HRP-coupled streptavidin and TMB-
substrate. Specific binding was calculated by subtracting the binding of mouse IgG
to the peptides. Alternatively, binding of anti-M7 was tested in western blot on cell
lysates from native CHO cells or CHO cells stably transfected with human Mac-1.
Full western blots are shown in Supplementary Figure 1. To test binding of the
antibody anti-M7 to human leukocytes, anti-M7 was labeled with Alexa Fluor-647
according to the manufacturer’s protocols (Monoclonal Antibody Labeling Kit, Life
Technologies). Human leukocytes were isolated from healthy donors by
centrifugation and Red Blood Cell lysis, and stimulated with PMA (200ng/ml),
incubated with anti-M7-Alexa 647 (1 μg and 5 μg) and antibody binding was
quantified by flow cytometry.
Antibody inhibition studies. For in vitro or in vivo use, the following antibodies
have been used: Anti-mouse Mac-1 (clone M1/70, ThermoFisher, Cat.Nr. 14-0112-
82), IgG2b-kappa (ThermoFisher Cat.Nr. 14-4732-82), anti-mouse ICAM-1
(clone YN1/1.7.4, Biolegend, Cat.Nr. 116101), anti-LFA-1 (clone M17/4,
BioLegend, Cat.Nr. 101118), anti-mouse RAGE (clone 697023, R&D, Cat.Nr.
MAB11795), anti-human Mac-1 (clone ICRF44, BioLegend, Cat.Nr. 301312), and
anti-human Mac-1 (clone 2LPM19c, GeneTex, Cat.Nr. GTX72023). Antibodies
were supplied as stock concentrations of 1 mg/ml are were diluted 1:100 for
in vitro experiment (final concentration of 10 μg/ml). For in vivo experiments,
antibodies were diluted 1:10 in sterile saline and 100μg were injected in a final
volume of 100 μl i.p.
Flow cytometry. Peritoneal exudate cells (PECs), mouse peripheral blood samples,
mouse splenocytes, or human blood samples from healthy volunteers were
obtained as described. Red blood cells were lysed by a RBC-lysis buffer
(eBioscience). Cells were washed multiple times in PBS and Fc-Receptors were
blocked by an anti-mouse CD16/CD32 antibody cocktail (Tonbo) for 10 min on
ice. Cells were then labeled with the indicated extracellular antibodies, and as
indicated fixed in 4%PFA, permeabilized, and stained with intracellular antibodies
before analysis on a flow cytometer (FACS Calibur or a FACS LSRII, BD
Biosciences). Distinct leukocyte populations were identified by the gating strategies
shown in Fig. 4 and Supplementary Figure 7, 15. As indicated, binding of the
complement factor iC3b was quantified by an anti-iC3B antibody after 30 min of
incubation with rat serum (source of iC3b). Apoptosis was quantified by binding of
Annexin-V-Alexa488 and incubation in a Ca2+ rich Annexin-V-binding buffer
(BioLegend, Cat. No. 640945). Generation of reactive oxygen species (ROS) was
quantified by incubation of cells with 1,2,3 Dihydrorhodamine (123 DHR,
Invitrogen) for 30 min in the cell culture incubator at 37 °C. Uptake of Alexa Fluor
488-labeld E. coli (Molecular Probes, Cat. E-13231) was evaluated by co-incubation
of peritoneal macrophages with bacteria in the presence of freshly prepared
opsonizing reagent (Molecular Probes, Cat E-2870) for 30 min and subsequent
quantification of Alexa Fluor 488+ macrophages. Cytokine production in human
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monocyte-derived macrophages (CD68+) was quantified in intracellular flow
cytometry by the following antibodies: anti-human TNFα, clone Mab11, Biolegend,
Cat.Nr. 502915), anti-human IL-6 (clone MQ2-13A5, Biolegend, Cat.Nr. 501114),
and anti-human MCP-1 (clone 5D3-F7, Biolegend, Cat. No. 502604).
Static and dynamic adhesion assay. 96-well plates (Nunc) were coated with
human sCD40L (Biozol, Germany) or human fibrinogen, ICAM-1, heparin,
RAGE, vitronectin, JAM-C, or NIF (10 μg/ml, all from R&D Systems, USA) and
incubated with CHO cells expressing constitutively activated, human Mac-1
(Mac-1 del) or CHO cells expressing the naïve, non-activated Mac-1 (Mac-1 WT)
43. As controls, CHO cells expressing no integrin (CHO) were used. Cells were
pre-incubated with blocking antibodies (10 μg/ml) for 15 min and allowed to
adhere for 50 min. Adhering cells were counted after repeated washing with PBS.
Alternatively, we tested the adhesion of primary mouse peritoneal macrophages to
mouse CD40L (R&D Systems, USA). For dynamic adhesion assays, mouse
endothelial cell cultures (HUVECs) were grown to confluency in 35 mm cell
culture dishes as previously described41, stimulated with TNFα overnight, and
placed in a parallel flow chamber system (Glycotech). The number of adhering
cells was quantified at the indicated shear rate in the presence of the indicated
antibodies (10 μg/ml).
Fab fragment preparation. Before enzymatic digestion, antibodies were dialyzed in
a SnakeSkin Dialysis Tubing 10 k MWCO against PBS overnight at 4 °C.
Immobilized papain was used to prepare Fab fragments from the indicated
antibodies according to the manufacturer’s instructions (Pierce Fab Preparation Kit,
Thermo Scientific). Briefly, Fab fragments were generated in the presence of 25 mM
cysteine for 3 h at 37 °C, followed by purification on Protein-A Spin Columns.
Purity of Fab fragments was validated by SDS–PAGE.
Isolation and mouse peritoneal macrophages/sterile peritonitis. 2 ml of 4%
thioglycollate broth (Sigma) were injected into 8-week-old, male C57Bl/6 mice. A
peritoneal lavage was performed after 72 h. Peritoneal exudate cells (PECs) were
identified as described above.
Differentiation of human monocyte-derived macrophages. Peripheral blood
mononuclear cells (PBMCs) were isolated from fresh human buffy coats (Trans-
fusion Medicine, University Hospital Freiburg, Freiburg, Germany) in CPT tubes
(BD Bioscience) by gradient centrifugation. PBMCs were collected, washed in
RPMI-1640 (10% FCS, 5% Human serum albumin, 1% Penicillin/Streptomycin),
and plated out in tissue culture dishes at a density of 2 × 106 cells/ml for 24 h. After
24 h, cells were washed with RPMI1-640 to remove non-adherent cells and cul-
tured for another 7 days in cell culture media supplemented with 10 ng/ml M-CSF.
Purity of macrophages was confirmed by expression of CD68 and Mac-1.
Human neutrophil isolation. Heparinized whole blood was obtained from healthy
human donors after informed consent, as approved by the Institutional Review
Board of the La Jolla Institute, La Jolla, USA. Neutrophils were isolated by using a
sodium metrizoate/Dextran 500 density gradient (Polymorphprep). After cen-
trifugation at 500 g for 35 min at room temperature, neutrophils were collected
from the resulting intermediate layer. Neutrophils were washed with PBS without
Ca2+ and Mg2+ twice to avoid integrin activation. Neutrophils were 95% pure, kept
in 2% HAS/RPMI-1640, and were used within 4 h. Neutrophils were incubated
with anti-human Fc-blocking antibodies (anti-CD16/CD32) for 10 min at room
temperature before all experiments.
Cell signaling studies. Mouse peritoneal macrophages were obtained as described
above. Flow cytometry revealed that the majority (>90%) of PECs were positive for
the macrophage marker F4/80. After overnight starvation, macrophages were co-
incubated with an anti-CD16/CD32 Fc-blocking antibody cocktail before addition
of the indicated antibody clones against Mac-1 (10 μg/ml) for 30 min. At the
indicated time points, cells were lysed, proteins were separated by SDS–PAGE and
blotted to polyvinylidene difluoride membranes. Total protein and the phos-
phorylated fraction of NFκB, ERK1/2 and p38 were detected by specific antibody
binding (Cell Signaling) in western blot. The ratio of phosphorylated fractions was
calculated and expressed as relative arbitrary unit (AU) normalized to the signal of
cells incubated with saline alone. Human macrophages were stimulated with anti-
human antibodies for 5 h as described above before an intracellular staining for the
indicated cytokines. Cells were analyzed in flow cytometry. Full western blots are
shown in Supplementary Figure 5, 6.
Integrin activation assay. Human neutrophils were enriched by density cen-
trifugation of peripheral blood as described above. During acquisition in flow
cytometry, the anti-β2 antibodies Mab24 (detecting the β2 high-affinity con-
formation) and KIM127 (for β2-extension) were added at the indicated time point.
120 s later, anti-M7 or IgG (10 μg/ml) antibodies, and 360 s later human IL-8 was
added during continuous acquisition over time. Recording was stopped at 600 s as
previously reported47. The mean fluorescence intensity (MFI) for Mab24 and
KIM127 was continuously recorded within the neutrophil gate and quantified as %
of the starting MFI (directly after addition of Mab24 and KIM127).
Intravital microscopy. Quantification of leukocyte recruitment was performed as
previously reported41,68. Mice received an intraperitoneal injection of 100 μg of
whole IgG antibodies or 50μg of Fab fragments i.p. After 15 min, mice were injected
i.p. with 200 ng murine TNFα (R&D Systems, USA) and surgery started 4 h later.
Briefly, mice were anesthetized by intraperitoneal injection of ketamine hydro-
chloride (Essex, USA) and xylazin (Bayer, Germany). The mesentery was exter-
iorized and placed under an upright intravital microscope (AxioVision, Carl Zeiss,
Germany). Videos of rolling and adhering in mesenteric venules were taken after
retro-orbital injection of rhodamine. Rolling leukocyte flux was defined as the
number of leukocytes moving at a velocity less than erythrocytes. Adherent leu-
kocytes were defined as cells that remained stationary for at least 30 s. Intravital
imaging of the greater omentum in LysM-GFP mice69 has been previously
described44. Briefly, after anesthesia, the omentum was exteriorized via a small
median incision and carefully mounted on a coverslip. Antibodies (100μg) were
injected 5 min prior to TNFα (500 ng/ml), which was applied locally to induce
inflammation. 90 min later, imaging was started. Throughout the experiment, the
specimen was kept moist using PBS. Anti-CD31-PE (10 μg/mouse, azide-free, clone
390) and Evans Blue was injected i.v. to visualize the circulation. Due to the high
permeability in omental milky spots, Evans Blue is also apparent in the par-
enchyma and served as surrogate marker for endothelial leakage. A SP5 microscope
(Leica) in point-scanning confocal mode equipped with a 20x/0.70 HCX PL APO
objective was used for imaging z-stacks at 512 × 512 pixels 10 μm apart every 8 s.
Post-processing included linear contrast adjustment, motion correction and cell
tracking using ImageJ and Imaris (Bitplane).
LPS-induced inflammation. A systemic inflammatory response syndrome (SIRS)
was induced in 8-week-old, male C57Bl/6 mice by an i.p. injection of 20μg LPS
(0111:B4, Invivogen, USA). Simultaneously, Fab fragment preparations of the
indicated antibodies (50 μg of IgG, anti-M7, or anti-mouse Mac-1 (clone M1/70))
were injected i.p. After 20 h, mice were killed and a peritoneal lavage was per-
formed. Cell infiltration in the peritoneal cavity was calculated as follows: total
count of cells (within the size range of 5 to 15 μm, assessed by a Beckman Coulter
Z2 cell counter) x fraction of cell sub-population of all leukocytes in flow cytometry
and subsequent normalization as % of cell numbers in the IgG-treated control in
the same experimental cohort.
Cecal ligation and puncture. Surgical induction of polymicrobial sepsis was
performed according to available standard protocols70. The peritoneal cavity
of 8- or 40-week old male C57Bl/6 mice was opened during ketamine/xylazin
anesthesia, and the cecum was exteriorized and ligated about 2 mm distal of the
ileo-cecal valve using a non-absorbable 6–0 suture. As indicated, 8-week-old female
C57Bl/6 mice were tested in addition. The distal end of the cecum was then
perforated using a 23 G or a 30 G needle as indicated, and a small drop of feces was
extruded through the puncture. The cecum was relocated into the peritoneal
cavity, and the peritoneum was closed by a suture. Buprenorphine was applied
as s.c. injection. 1 h before or 2 h after surgery Fab fragment preparations of the
indicated antibodies (50 μg of IgG, anti-M7, or anti-mouse Mac-1 (clone M1/70))
were injected i.p. After 20 h, mice were killed and a peritoneal lavage was
performed. Organs were prepared for cell isolation or histology. A plasma
sample was stored at −20 °C for further analysis. Alternatively, a set of mice was
followed up in survival analysis and received additional antibody injections
at 48 and 96 h after surgery. Cell infiltration in the peritoneal cavity was calculated
as described above.
Analysis of murine plasma and peritoneal lavage samples. Plasma levels of
Serum Amyloid-A (SAA), the mouse analog for C-reactive protein (CRP), were
measured by ELISA, according to the manufacturer’s protocols (USCN Life Sci-
ence). Cytokines in the plasma were determined by a cytometric bead array (CBA,
BD Biosciences), according to the manufacturer’s protocol. LPS titers in plasma
and peritoneal lavage samples were quantified by a Limulus assay (Lonza), IgM
titers by a ELISA (R&D Systems, USA).
Statistical analysis. Data are presented as mean± SEM. Statistical testing
employed an unpaired, two-sided Student’s T-test between the indicated groups.
P-values are indicated in each Figure legend. Survival was calculated using
Kaplan–Meier curves and tested by log-rank test. Probability values <0.05 were
considered significant.
Data availability. All relevant data are available from the authors upon request.
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